Skip to main content

IBM Delivers Industry's Most Comprehensive Solution For Integrating Life Sciences Data

Aventis, Schering and Spotfire Use DiscoveryLink to Speed Drug Discovery

Select a topic or year


SAN DIEGO, CA - 25 Jun 2001: IBM today announced the newest version of DiscoveryLink* and named three new partners and customers that are using the data integration software and services to enhance drug discovery and development.

At the BIO 2001 Conference, IBM unveiled a new partnership with eAnalytic applications provider Spotfire Inc., and two new pharmaceutical users -- Aventis and Schering AG, which is utilizing DiscoveryLink as part of a technology platform implemented by IBM business partner NetGenics Inc.

The announcement underscores IBM's commitment to work closely with life sciences companies to offer technology that addresses one of their biggest challenges: the integration and management of an ever-growing amount of disparate biological and chemical data.

The Federated Data Approach
IBM DiscoveryLink employs a federated data model with an industry-leading optimized query engine, which makes searches faster and more efficient. Using DiscoveryLink, scientists can easily search diverse data sources and file types and get a single-format view of information, without moving the data or changing its underlying format. For example, a researcher will be able to compare a target drug with similar compounds by using DiscoveryLink to perform simultaneous queries against internal and external data sources. DiscoveryLink will access and deliver the information in a consolidated, consistent format.

"We have research organizations in four countries that need to collaborate and share chemical compound and biomedical data, from sources within Aventis and many public databases," said Peter Loupos, Aventis' global head of Drug Innovation and Approval Information Systems. "DiscoveryLink allows us to access and mine the physical data in a way never before possible, significantly speeding up the drug discovery and development process."

DiscoveryLink will be showcased at the BIO 2001 Conference as an integral part of the Interoperable Informatics Infrastructure Consortium's (I3C) first demonstration of interoperability of life sciences applications.

DiscoveryLink Adoption
"A major milestone is being marked today with the deployment of DiscoveryLink at Aventis and Schering AG," said Dr. Caroline Kovac, vice president, IBM Life Sciences. "We've also forged a number of significant alliances with life sciences companies who will use DiscoveryLink to complement their technologies. Working together, we will provide more comprehensive solutions to customers' data analysis and integration needs."

Today's announcement of a new partnership with Spotfire (Editors: please see separate press release for details) adds to the growing list of life sciences solutions providers and biotechnology companies that are utilizing DiscoveryLink as part of their offerings. Aventis is implementing an end-to-end drug discovery system, which includes IBM's data integration platform and Spotfire's eAnalytic** applications.

"There's no doubt that computing power is driving the next generation of life sciences and enabling researchers to uncover, with greater speed and accuracy, new products to improve the quality of life," said Rock Gnatovich, president, Spotfire. "By meshing our analytic capabilities with IBM's data management technology, we've created a complete solution to handle the incredible demand for technologies that can transform information-intensive processes into breakthrough discoveries."

IBM announced an agreement in April with NetGenics Inc. to bundle DiscoveryLink as part of NetGenics' DiscoveryCenter** product. Schering AG (FSE: SCH, NYSE: SHR) has selected NetGenics to build a custom gene data integration solution that will be used by hundreds of scientists around the world.

As a central location for gene data, the Schering AG system will support collaboration and data sharing, and will provide easy access to proprietary and public gene resource databases. The aim is to provide Schering AG scientists with a single, central point of access to curated and annotated gene data, sequence data, and expression data.

"The collaboration between NetGenics and IBM is enabling Schering AG to enhance the speed and competitiveness of their target identification and validation efforts," said Manuel Glynias, NetGenics' president and CEO. "DiscoveryLink represents a keystone data access and integration technology that allows NetGenics to deliver much greater benefits to our customers."

New DiscoveryLink Features
The new version of DiscoveryLink, based on the recently announced DB2* Universal Database V7.2, offers a number of features that provides life sciences researchers with more powerful data searching and mining capabilities, as well as easier administration of IT systems:

New DiscoveryLink Services
DiscoveryLink users can draw on a breadth of services offered by IBM Global Life Sciences Consulting and Solutions. A new data management offering, High-Performance Data Exploration, allows researchers and scientists to leverage the DiscoveryLink technology for complex queries and analyses, including predictive modeling to analyze complex relationships between biological, structural, chemical and textual data. This capability is critical in accelerating drug discovery activities and identifying new compounds to fight disease.

Other services offerings include: requirements assessment; solution design and implementation services; and enterprise-wide deployment. IBM Global Services also provides application hosting and maintenance services for DiscoveryLink and other scientific applications.

Related XML feeds
Topics XML feeds
Services and solutions
Software
Information Management, Lotus, Tivoli, Rational, WebSphere, Open standards, open source